FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952006302> ?p ?o ?g. }

• W2952006302 endingPage "750" @default.
• W2952006302 startingPage "749" @default.
• W2952006302 abstract "Background: Autologous stem cell transplantation (auto-SCT) is considered the standard treatment for patients with relapsed or refractory (R/R) Hodgkin lymphoma (HL). For those with high-risk disease, such as those with a short interval from diagnosis to auto-SCT or those who have received multiple lines of therapy, an alternative consolidation strategy with allogeneic SCT (allo-SCT) could be a potential option to improve the outcome. However, allo-SCT with a reduced-intensity conditioning (RIC) needs around 3 months for the graft-versus-lymphoma effect (GVL) to develop, thus in patients with an aggressive HL the disease might progress before this happens. In this setting, a tandem auto-RIC-SCT approach has the potential of combining cytoreduction to keep the lymphoma under control and the potential benefit of a GVL effect. Aims: We conducted a retrospective analysis of patients treated with this strategy between January 2004 and December 2015 and reported to the EBMT registry to analyze its efficacy in high-risk patients. Methods: Patients were included if they had received an auto-SCT followed by a planned RIC-SCT in <6 months with no disease relapse between the procedures. The primary endpoint was progression-free survival (PFS) after the tandem procedure. Results: One-hundred and thirty patients [58% male, median age at auto-SCT, 30 years (range: 18–65)] fulfilled the inclusion criteria. The median time between diagnosis (Dx) and auto-SCT was 16 months (range: 2–174); with 21% of the patients having an interval Dx-autoSCT of ≤12 months; the median number of lines prior to auto-SCT 2 (2–4) and one third of the patients received ≥3 lines of therapy prior to auto-SCT. Disease status at auto-SCT was complete response in 32%, partial response in 27% and the remaining 41% were transplanted with active disease. The median time from auto to allo-SCT was 3 months (1–6). Forty percent underwent an identical sibling allo-SCT, 39% unrelated and 21% haplo. TBI was used in 35% of the patients as a part of RIC. GVHD prophylaxis was cyclosporine-methotrexate in 36% of the patients, cyclosporine-micofenolate mofetil in 16% and post-transplant cyclophosphamide in the remaining 17%. 91% of the patients engrafted after RIC-SCT. After a median follow-up of 44 months (6–130), 33% of the patients have relapsed and 34% died. The main causes of death were SCT-related in 53% and disease in 35%. 3y-PFS, OS, IR and NRM were 53% (44–63), 72% (64–80), 34% (25–43) and 13% (8–20), respectively. 3y-PFS and OS were 49% and 69%, respectively, for patients who received an auto-SCT ≤12 months from diagnosis, whereas it was 54% and 72%, respectively, for those with an interval >12 months (p = NS for PFS and OS). There were no significant differences in PFS or OS according to the number of prior treatment lines: 3y-PFS and OS of were 45% and 62% for patients with ≥3 lines in comparison with 57% and 77% (p = NS) for patients who had received <3 lines. Summary/Conclusion: This is the largest series analysing the efficacy and safety of a tandem auto-RIC-SCT approach in R/R HL. The low NRM and IR with promising PFS and OS suggest that this might be an effective procedure. Around half the patients with a time from diagnosis to auto-SCT <12 months or ≥3 lines of treatment before auto-SCT remain free of disease at 3 years, suggesting that this high risk population could benefit from this approach." @default.
• W2952006302 created "2019-06-27" @default.
• W2952006302 creator A5001904777 @default.
• W2952006302 creator A5002261559 @default.
• W2952006302 creator A5003809364 @default.
• W2952006302 creator A5007895303 @default.
• W2952006302 creator A5021060422 @default.
• W2952006302 creator A5021867441 @default.
• W2952006302 creator A5022018542 @default.
• W2952006302 creator A5025988073 @default.
• W2952006302 creator A5036207495 @default.
• W2952006302 creator A5045925835 @default.
• W2952006302 creator A5046040335 @default.
• W2952006302 creator A5053560614 @default.
• W2952006302 creator A5056514957 @default.
• W2952006302 creator A5061020169 @default.
• W2952006302 creator A5065734954 @default.
• W2952006302 creator A5066352955 @default.
• W2952006302 creator A5069084023 @default.
• W2952006302 creator A5077430940 @default.
• W2952006302 creator A5086577784 @default.
• W2952006302 creator A5087171473 @default.
• W2952006302 creator A5089360800 @default.
• W2952006302 date "2019-06-01" @default.
• W2952006302 modified "2023-10-18" @default.
• W2952006302 title "S1622 TANDEM AUTOLOGOUS-REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN HIGH-RISK RELAPSED HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY OF THE LWP-EBMT" @default.
• W2952006302 doi "https://doi.org/10.1097/01.hs9.0000564736.59814.ec" @default.
• W2952006302 hasPublicationYear "2019" @default.
• W2952006302 type Work @default.
• W2952006302 sameAs 2952006302 @default.
• W2952006302 citedByCount "2" @default.
• W2952006302 countsByYear W29520063022020 @default.
• W2952006302 countsByYear W29520063022022 @default.
• W2952006302 crossrefType "journal-article" @default.
• W2952006302 hasAuthorship W2952006302A5001904777 @default.
• W2952006302 hasAuthorship W2952006302A5002261559 @default.
• W2952006302 hasAuthorship W2952006302A5003809364 @default.
• W2952006302 hasAuthorship W2952006302A5007895303 @default.
• W2952006302 hasAuthorship W2952006302A5021060422 @default.
• W2952006302 hasAuthorship W2952006302A5021867441 @default.
• W2952006302 hasAuthorship W2952006302A5022018542 @default.
• W2952006302 hasAuthorship W2952006302A5025988073 @default.
• W2952006302 hasAuthorship W2952006302A5036207495 @default.
• W2952006302 hasAuthorship W2952006302A5045925835 @default.
• W2952006302 hasAuthorship W2952006302A5046040335 @default.
• W2952006302 hasAuthorship W2952006302A5053560614 @default.
• W2952006302 hasAuthorship W2952006302A5056514957 @default.
• W2952006302 hasAuthorship W2952006302A5061020169 @default.
• W2952006302 hasAuthorship W2952006302A5065734954 @default.
• W2952006302 hasAuthorship W2952006302A5066352955 @default.
• W2952006302 hasAuthorship W2952006302A5069084023 @default.
• W2952006302 hasAuthorship W2952006302A5077430940 @default.
• W2952006302 hasAuthorship W2952006302A5086577784 @default.
• W2952006302 hasAuthorship W2952006302A5087171473 @default.
• W2952006302 hasAuthorship W2952006302A5089360800 @default.
• W2952006302 hasBestOaLocation W29520063021 @default.
• W2952006302 hasConcept C121332964 @default.
• W2952006302 hasConcept C126322002 @default.
• W2952006302 hasConcept C141071460 @default.
• W2952006302 hasConcept C142424586 @default.
• W2952006302 hasConcept C143998085 @default.
• W2952006302 hasConcept C167135981 @default.
• W2952006302 hasConcept C203092338 @default.
• W2952006302 hasConcept C2776694085 @default.
• W2952006302 hasConcept C2777408962 @default.
• W2952006302 hasConcept C2779050716 @default.
• W2952006302 hasConcept C2779338263 @default.
• W2952006302 hasConcept C2780775027 @default.
• W2952006302 hasConcept C2911091166 @default.
• W2952006302 hasConcept C535046627 @default.
• W2952006302 hasConcept C71924100 @default.
• W2952006302 hasConcept C87355193 @default.
• W2952006302 hasConceptScore W2952006302C121332964 @default.
• W2952006302 hasConceptScore W2952006302C126322002 @default.
• W2952006302 hasConceptScore W2952006302C141071460 @default.
• W2952006302 hasConceptScore W2952006302C142424586 @default.
• W2952006302 hasConceptScore W2952006302C143998085 @default.
• W2952006302 hasConceptScore W2952006302C167135981 @default.
• W2952006302 hasConceptScore W2952006302C203092338 @default.
• W2952006302 hasConceptScore W2952006302C2776694085 @default.
• W2952006302 hasConceptScore W2952006302C2777408962 @default.
• W2952006302 hasConceptScore W2952006302C2779050716 @default.
• W2952006302 hasConceptScore W2952006302C2779338263 @default.
• W2952006302 hasConceptScore W2952006302C2780775027 @default.
• W2952006302 hasConceptScore W2952006302C2911091166 @default.
• W2952006302 hasConceptScore W2952006302C535046627 @default.
• W2952006302 hasConceptScore W2952006302C71924100 @default.
• W2952006302 hasConceptScore W2952006302C87355193 @default.
• W2952006302 hasIssue "S1" @default.
• W2952006302 hasLocation W29520063021 @default.
• W2952006302 hasLocation W29520063022 @default.
• W2952006302 hasOpenAccess W2952006302 @default.
• W2952006302 hasPrimaryLocation W29520063021 @default.
• W2952006302 hasRelatedWork W1496133262 @default.
• W2952006302 hasRelatedWork W1841983458 @default.
• W2952006302 hasRelatedWork W1969631111 @default.
• W2952006302 hasRelatedWork W2004678634 @default.
• W2952006302 hasRelatedWork W2080234296 @default.

• next